Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Yuki Fujiwara to B7-H1 Antigen

This is a "connection" page, showing publications Yuki Fujiwara has written about B7-H1 Antigen.

 
Connection Strength
 
 
 
1.638
 
  1. Fujiwara Y, Sun Y, Torphy RJ, He J, Yanaga K, Edil BH, Schulick RD, Zhu Y. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity. Cancer Res. 2018 12 01; 78(23):6655-6665.
    View in: PubMed
    Score: 0.512
  2. Yamada H, Yano H, Matsubara E, Zhao S, Shinchi Y, Pan C, Koga T, Fujino K, Fujiwara Y, Ikeda K, Komohara Y, Suzuki M. The expression of PD-1 ligands in the immune microenvironment was altered in TTF-1-negative lung adenocarcinoma. Hum Cell. 2025 Aug 18; 38(5):146.
    View in: PubMed
    Score: 0.206
  3. Sonokawa T, Fujiwara Y, Pan C, Komohara Y, Usuda J. Enhanced systemic antitumor efficacy of PD-1/PD-L1 blockade with immunological response induced by photodynamic therapy. Thorac Cancer. 2024 06; 15(18):1429-1436.
    View in: PubMed
    Score: 0.188
  4. Saito Y, Fujiwara Y, Shinchi Y, Mito R, Miura Y, Yamaguchi T, Ikeda K, Urakami S, Nakashima Y, Sakagami T, Suzuki M, Tabata Y, Komohara Y. Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis. Cancer Sci. 2022 Sep; 113(9):3255-3266.
    View in: PubMed
    Score: 0.165
  5. Matsusaka K, Fujiwara Y, Pan C, Esumi S, Saito Y, Bi J, Nakamura Y, Mukunoki A, Takeo T, Nakagata N, Yoshii D, Fukuda R, Nagasaki T, Tanaka R, Komori H, Maeda H, Watanabe H, Tamada K, Komohara Y, Maruyama T. a1-Acid Glycoprotein Enhances the Immunosuppressive and Protumor Functions of Tumor-Associated Macrophages. Cancer Res. 2021 09 01; 81(17):4545-4559.
    View in: PubMed
    Score: 0.154
  6. Ma C, Horlad H, Pan C, Yano H, Ohnishi K, Fujiwara Y, Matsuoka M, Lee A, Niidome T, Yamanaka R, Takeya M, Komohara Y. Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. J Clin Exp Hematop. 2017 Jul 05; 57(1):21-25.
    View in: PubMed
    Score: 0.116
  7. Fukuda R, Fujiwara Y, Maeda H, Pan C, Minayoshi Y, Yano H, Mizuta Y, Takano M, Yamada R, Saito Y, Hirata K, Imoto S, Yamasaki K, Oniki K, Saruwatari J, Otagiri M, Watanabe H, Komohara Y, Maruyama T. Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages. Mol Cancer. 2025 May 03; 24(1):132.
    View in: PubMed
    Score: 0.050
  8. Anami T, Pan C, Fujiwara Y, Komohara Y, Yano H, Saito Y, Sugimoto M, Wakita D, Motoshima T, Murakami Y, Yatsuda J, Takahashi N, Suzu S, Asano K, Tamada K, Kamba T. Dysfunction of sinus macrophages in tumor-bearing host induces resistance to immunotherapy. Cancer Sci. 2024 Jan; 115(1):59-69.
    View in: PubMed
    Score: 0.045
  9. Matsubara E, Shinchi Y, Komohara Y, Yano H, Pan C, Fujiwara Y, Ikeda K, Suzuki M. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma. Med Mol Morphol. 2023 Dec; 56(4):250-256.
    View in: PubMed
    Score: 0.044
  10. Saito Y, Fujiwara Y, Miyamoto Y, Ohnishi K, Nakashima Y, Tabata Y, Baba H, Komohara Y. CD169+ sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer. Cancer Med. 2023 05; 12(9):10199-10211.
    View in: PubMed
    Score: 0.043
  11. Yonemitsu K, Pan C, Fujiwara Y, Miyasato Y, Shiota T, Yano H, Hosaka S, Tamada K, Yamamoto Y, Komohara Y. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer. Sci Rep. 2022 07 14; 12(1):12007.
    View in: PubMed
    Score: 0.041
  12. Shinchi Y, Ishizuka S, Komohara Y, Matsubara E, Mito R, Pan C, Yoshii D, Yonemitsu K, Fujiwara Y, Ikeda K, Tamada K, Sakagami T, Suzuki M. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother. 2022 Nov; 71(11):2645-2661.
    View in: PubMed
    Score: 0.041
  13. Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. Drug Deliv. 2018 Nov; 25(1):1067-1077.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)